ClinicalTrials.gov record NCT06417502

Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.The registry record was last updated on May 16, 2024, about 2 years ago, so the status shown may be out of date. The study team or the registry can confirm.
Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
AgeUp to 18 years old
SexAll
LocationChina
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

An observational, multi-center, prospective registry for Chinese children with rheumatic and immunologic diseases. It collects routine clinical data from hospital databases, a web-based registry, and a mobile app for long-term follow-up and patient-reported outcomes. No study interventions are assigned; treatment stays as decided by the treating clinicians.

What it is studying. The registry aims to gather real-world information about clinical features, diagnoses, complications, treatments, drug safety, adverse events, critical illness, and outcomes in Chinese pediatric patients with rheumatic and immunologic diseases, using standardized hospital databases and patient-reported data.

What the researchers hope to learn. To describe clinical phenotypes and diagnoses, monitor complications and outcomes, and collect real-world data on drug safety, therapeutic effectiveness, and adverse events in Chinese pediatric rheumatic and immunologic diseases; and to build standardized, multi-center data resources for research.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • Age <= 18 years old
  • Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity)
  • Diagnosed and Treated in China

Exclusion criteria

  • Disagreement of involving in this study by the patient or his/her family.

Study description and what participation involves

The study's detailed description, as published on ClinicalTrials.gov.

Detailed description from the registry

Pediatric rheumatic and immunologic diseases severely impact the health of children and adolescents. Chinese Alliance of Pediatric Rheumatic \& Immunologic Diseases (CAPRID) was founded in 2022 to form a national collaboration for high-quality data-driven multi-center pediatric rheumatology and immunology research in China. The CAPRID Registry is an observational, multi-center, longitudinal registry for Chinese pediatric patients with rheumatic and immunologic diseases to explore the clinical phenotypes, diagnoses, complications, real-world drug safety, therapeutic efficacy, adverse events, critical illness and outcomes of Chinese pediatric patients with rheumatic and immunologic diseases. Hospital-based databases are established and standardized with Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) for routine data collection. A web-based registry website is established with standardized electronic case report forms to register patients from CAPRID centers. A mobile application is created to allow long-term follow up and patient-reported outcome collection. The data captured in this registry reflects a "real world" situation with no intervention done outside the routine clinical practice. Treatment plans are determined by the investigator.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants allow their routine clinical data and test results to be entered into a web-based registry and standardized hospital database, and use a mobile app for long-term follow-up and patient/parent-reported outcomes. Care and treatment remain determined by the treating clinician; the registry does not assign treatments. Expected activities include periodic physician assessments, patient or parent global assessments (patients older than 8 may self-report), questionnaires such as the CHAQ, and collection of routine clinical and laboratory data over time (target follow-up ~3 years; some registry outcomes tracked up to 10 years).

How the study is structured. A prospective, observational, multi-center registry. Data are collected from hospital records standardized to a common data model, entered into a web registry, and supplemented by a mobile app for follow-up. Participants continue routine clinical care; the registry tracks outcomes over time (target duration listed as 3 years; some outcome measures noted up to 10 years).

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
  • The listed sites are in China. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on dermatomyositis

This trial is also listed on this site under polymyositis.

Clinical trials59 trials listed for dermatomyositisEvery trial the registry lists for dermatomyositis, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in dermatomyositis researchLatest monthly update: September 2026. Includes: Upadacitinib case reports. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
Apr 29, 2022
Primary completion
Nov 30, 2024 (estimated)
Study completion
Dec 31, 2031 (estimated)
Target enrollment
20000 participants (estimated)
Last updated on registry
May 16, 2024
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Peking Union Medical College Hospital
Principal investigator
Hongmei Song, MD
Peking Union Medical College Hospital
Collaborators
  • Children's Hospital of Chongqing Medical University
  • Central South University
  • Beijing Children's Hospital
  • Shenzhen Children's Hospital
  • Children's Hospital of Nanjing Medical University
  • The University of Hong Kong
  • Zhejiang University
  • Peking University Third Hospital

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (9)

  • Peking Union Medical College HospitalRecruiting

    Beijing, Beijing Municipality, 100730 · China

  • Beijing Children's Hospital, Capital Medical UniversityRecruiting

    Beijing, Beijing Municipality · China

    • Huawei Mao, MD, PhD
  • Third Hospital of Peking UniversityRecruiting

    Beijing, Beijing Municipality · China

    • Zhiqiang Yan, PhD
  • Chidren's Hospital of Chongqing Medical UniversityRecruiting

    Chongqing, Chongqing Municipality · China

    • Xuemei Tang, MD
  • Shenzhen Children's HospitalRecruiting

    Shenzhen, Guangdong · China

    • Jun Yang, MD
  • The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI)Recruiting

    Shenzhen, Guangdong · China

    • Wanling Yang, PhD
  • The Second Xiangya Hospital of Central South UniversityRecruiting

    Changsha, Hunan · China

    • Xiaochuan Wu, MD
  • Children's Hospital of Nanjing Medical UniversityRecruiting

    Nanjing, Jiangsu · China

    • Haiguo Yu, MD
  • Children's Hospital of Zhejiang University School of MedicineRecruiting

    Hangzhou, Zhejiang · China

    • Meiping Lu, MD

Terms used on this page · explanations by MedicalUpdates.ai

registry
An organised collection of information about people with a particular condition, gathered over time for research. Joining a registry usually means sharing medical information, not receiving a treatment.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
adverse events
Any unwanted medical problem that happens during a study, whether or not it was caused by the treatment. A 'serious' adverse event is one that meets specific criteria, such as causing death, being life-threatening, requiring or prolonging hospital admission, causing significant disability, or another medically important outcome.
follow up
The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
no intervention
A study group that does not receive the intervention being tested and is observed for comparison.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials